Evaluation of the Quality and Trustworthiness of Short Videos on Renal Cell Carcinoma Available on Bilibili and TikTok: A Cross-Sectional Analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluation of the Quality and Trustworthiness of Short Videos on Renal Cell Carcinoma Available on Bilibili and TikTok: A Cross-Sectional Analysis

  • By

  • Jianzhi Su

  • Helong Xiao

  • Qinghui Xiao

  • Ren Xu

  • Yanan Ren

  • Luyang Su

  • Changjin Shi

  • January 1, 2026

Share

  • 1

    Renal cell carcinoma (RCC) is the most common kidney malignancy, with rising global incidence and significant public health implications.

  • 2

    Short-video platforms like Bilibili and TikTok are increasingly used for health information, especially among younger populations.

  • 3

    The accuracy and reliability of RCC-related content on short-video platforms are concerning, with previous studies highlighting inconsistent information quality.

  • 4

    This study aims to systematically evaluate the quality and reliability of RCC-related videos on Bilibili and TikTok to guide patients toward accurate information.

  • 5

    Video quality was assessed using the Global Quality Scale, while reliability was evaluated with the modified DISCERN instrument by experienced urologists.

Original Source(s)

Evaluation of the Quality and Trustworthiness of Short Videos on Renal Cell Carcinoma Available on Bilibili and TikTok: A Cross-Sectional Analysis

  • by Jianzhi Su, Helong Xiao, Qinghui Xiao, Ren Xu, Yanan Ren, Luyang Su, Changjin Shi

  • January 1, 2026

Related Content

Evaluation of Treatment Response in Patients with Locally Advanced Renal Cell Carcinoma Following Previous Systemic Therapy

Bioinformatics Investigations Uncover the Involvement of RIPK1 in Clear Cell Renal Cell Carcinoma

This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark

REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR

  • May 25, 2026

  • 7 min